Cancer pain is a complex form of chronic pain to treat because it typically involves mixed nociceptive and neuropathic pain resulting from multiple causes (e.g., chemotherapy, metastases)…
Acute myeloid leukemia (AML) is the most common form of adult leukemia but has the lowest five-year overall survival rates of all blood cancers. Historically, AML treatment in China has been…
Hepatocellular carcinoma, the most common type of primary liver cancer, occurs as a results of chronic liver cirrhosis and has a five-year survival rate of only 18%. First-line advanced…
China has the highest incidence of gastroesophageal cancer globally, and therapeutic options are limited. Only five targeted agents are approved to treat this indication—Roche’s Herceptin as…
Non-small-cell lung cancer (NSCLC)—the leading cause of cancer-related deaths in China—has a highly dynamic drug development pipeline, with multiple targeted and biomarker-driven therapies…
DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key endometrial cancer patient populations covering 171 countries and more than…
Nonalcoholic steatohepatitis (NASH) has the potential to be a large and lucrative therapy market owing to the prevalence of the disease and the lack of approved agents. Patients with NASH are at…
The bladder cancer market has seen a tremendous uptake of immune checkpoint inhibitors with their approval in the locally advanced / metastatic setting and, in the case of Merck & Co.’s Keytruda…
The treatment of neuropathic pain involves the use of drugs from several drug classes, including antidepressants, antiepileptic drugs, local anesthetics, dual-acting opioid analgesics, and opioid…
KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand which drugs to…
Despite the number of therapy options available, advanced or metastatic HR-positive / HER2-negative breast cancer remains incurable and a major cause of mortality and morbidity in women. Later-line…
DRG Epidemiology's coverage of colorectal cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of…
The high number of premium-priced non-small-cell lung cancer (NSCLC) therapies and the large number of NSCLC patients have resulted in a significant financial burden for payers. Costs are set to…
KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand which drugs to…
Seven premium-priced therapies (Avastin, Erbitux, Vectibix, Zaltrap, Stivarga, Lonsurf, and Cyramza) and three immune checkpoint inhibitors (Keytruda, Opdivo, and Yervoy) are FDA-approved to treat…